PharmacyCodes



Vincristinum [INN-Latin] en es it fr

Vincristinum [INN-Latin] Brand names, Vincristinum [INN-Latin] Analogs

Vincristinum [INN-Latin] Brand Names Mixture

  • No information avaliable

Vincristinum [INN-Latin] Chemical_Formula

C46H56N4O10

Vincristinum [INN-Latin] RX_link

http://www.rxlist.com/cgi/generic3/vincristine.htm

Vincristinum [INN-Latin] fda sheet

http://www.accessdata.fda.gov/scripts/cder/onctools/summary.cfm?ID=35

Vincristinum [INN-Latin] msds (material safety sheet)

Vincristinum_[INN-Latin] MSDS

Vincristinum [INN-Latin] Synthesis Reference

No information avaliable

Vincristinum [INN-Latin] Molecular Weight

824.958 g/mol

Vincristinum [INN-Latin] Melting Point

220 oC

Vincristinum [INN-Latin] H2O Solubility

No information avaliable

Vincristinum [INN-Latin] State

Solid

Vincristinum [INN-Latin] LogP

4.918

Vincristinum [INN-Latin] Dosage Forms

Liquid; Solution

Vincristinum [INN-Latin] Indication

For treatment of acute leukaemia, malignant lymphoma, Hodgkin's disease, acute erythraemia, acute panmyelosis

Vincristinum [INN-Latin] Pharmacology

Vincristine is a vinca alkaloid antineoplastic agent used as a treatment for various cancers including breast cancer, Hodgkin's disease, Kaposi's sarcoma, and testicular cancer. The vinca alkaloids are structurally similar compounds comprised of 2 multiringed units, vindoline and catharanthine. The vinca alkaloids have become clinically useful since the discovery of their antitumour properties in 1959. Initially, extracts of the periwinkle plant (Catharanthus roseus) were investigated because of putative hypoglycemic properties, but were noted to cause marrow suppression in rats and antileukemic effects in vitro. Vincristine binds to the microtubular proteins of the mitotic spindle, leading to crystallization of the microtubule and mitotic arrest or cell death. Vincristine has some immunosuppressant effect. The vinca alkaloids are considered to be cell cycle phase-specific.

Vincristinum [INN-Latin] Absorption

No information avaliable

Vincristinum [INN-Latin] side effects and Toxicity

IVN-RAT LD50 1300 mg/kg; IPR-MUS LD50 5.2 mg/kg

Vincristinum [INN-Latin] Patient Information

PATIENT INFORMATION

Follow the links

http://www.rxlist.com/cgi/generic3/vincristine_wcp.htm

http://www.drugs.com/cons/Vincristine.html

Vincristinum [INN-Latin] Organisms Affected

Humans and other mammals